Author

C. M. Morrissey

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Approach:machine learning (classical)· 1 Organism:mouse· 1

Frequent Co-Authors

A. Aguda· 1 shared A. Barlas· 1 shared A. Gopalan· 1 shared A. Jungbluth· 1 shared A. Obradovic· 1 shared A. Zoubeidi· 1 shared C. Sawyers· 1 shared D. Ganguli· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Aguda

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Single Cell Analysis of Treatment-Resistant Prostate Cancer: Implications of Cell State Changes for Cell Surface Antigen Targeted Therapies

S. Zaidi, J. Park, J. M. Chan, M. Roudier, J. L. Zhao, A. Gopalan, K. M. Wadosky, R. A. Patel, E. Sayar, W. R. Karthaus, D. H. Kates, O. Chaudhary, T. Xu, I. Masilionis, L. Mazutis, , C. Sawyers

The paper uses single-cell analysis to study how cell surface antigen expression changes in treatment-resistant prostate cancer, revealing transcriptional heterogeneity and shared gene regulatory networks between NEPC and SCLC.

bioRxiv · Apr 9, 2024 · PreprintCancer Biology

Discovery and characterization of a first-in-field transcription factor BRN2 inhibitor for the treatment of neuroendocrine prostate cancer.

D. Thaper, R. Munuganti, A. Aguda, S. Kim, S.-y. Ku, O. Sivak, S. Kumar, S. Vahid, D. Ganguli, H. Beltran, C. M. Morrissey, E. Corey, A. Zoubeidi

This paper develops and characterizes B18-94, the first BRN2 inhibitor, showing efficacy in reducing NEPC tumor growth with no toxicity.

bioRxiv · May 4, 2022 · PreprintCancer Biology